A client asks you to 'include ESG in the valuation'. What are the defensible ways to do that — and which popular approach do you push back on?
A core Valuation interview question — asked in analyst and associate interviews across IB, PE, and the Big 4.
THE SHORT ANSWER
The defensible route is through the cash flows and scenarios, because that forces explicitness: quantify transition effects (carbon pricing on the cost base, required transition capex, demand shifts for affected products), physical-risk effects where material, and regulation-driven costs (CBAM, energy standards), each with a timeline and probability. Where effects are real but hard to time, scenario analysis with weighted outcomes beats a single adjusted number. The approach to push back on is the arbitrary discount-rate tweak — 'add 100bp for poor ESG' — because it hides the judgment, compounds forever in the terminal value, and double-counts risks already reflected in cash-flow scenarios. A rate adjustment is defensible only where evidence supports a financing-cost channel: demonstrably higher funding costs, or restricted investor demand for the sector. Also distinguish values-based screening from value-based analysis: excluding a sector is a mandate decision, not a valuation input. Document which channel every ESG effect flows through — cash flow, growth, or discount rate — and never the same effect through two channels.
WHAT INTERVIEWERS LISTEN FOR
- ✓prefer explicit cash-flow and scenario modelling
- ✓carbon pricing, transition capex, demand shifts with timelines
- ✓arbitrary WACC add-ons hide judgment and compound in TV
- ✓rate channel only with financing-cost evidence
- ✓one channel per effect, no double-counting
COMMON MISTAKES
- ✗unexplained ESG premium/discount on WACC
- ✗same risk in both cash flows and discount rate
You've seen the model answer. Now get graded on yours.
In the interview you won't have this page — you deliver your version on a clock. Practice this and 1,000+ questions with AI feedback on every answer.
RELATED QUESTIONS
- How do you value a company with no revenue?
- Explain accretion/dilution analysis.
- How would you value a company in a cyclical industry?
- What is the most appropriate valuation methodology for a company with significant intangible assets but no current revenue, such as a biotech startup in the pre-clinical stage?
- When calculating WACC for a company with multiple divisions in different countries, what is the correct approach?
- How does a private equity buyer use an LBO to set the maximum price it can pay, and why is this a valuation floor?